These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
266 related articles for article (PubMed ID: 9407392)
1. Canavan disease. Analysis of the nature of the metabolic lesions responsible for development of the observed clinical symptoms. Baslow MH; Resnik TR J Mol Neurosci; 1997 Oct; 9(2):109-25. PubMed ID: 9407392 [TBL] [Abstract][Full Text] [Related]
2. N-acetylaspartate supports the energetic demands of developmental myelination via oligodendroglial aspartoacylase. Francis JS; Wojtas I; Markov V; Gray SJ; McCown TJ; Samulski RJ; Bilaniuk LT; Wang DJ; De Vivo DC; Janson CG; Leone P Neurobiol Dis; 2016 Dec; 96():323-334. PubMed ID: 27717881 [TBL] [Abstract][Full Text] [Related]
3. Uncoupling N-acetylaspartate from brain pathology: implications for Canavan disease gene therapy. von Jonquieres G; Spencer ZHT; Rowlands BD; Klugmann CB; Bongers A; Harasta AE; Parley KE; Cederholm J; Teahan O; Pickford R; Delerue F; Ittner LM; Fröhlich D; McLean CA; Don AS; Schneider M; Housley GD; Rae CD; Klugmann M Acta Neuropathol; 2018 Jan; 135(1):95-113. PubMed ID: 29116375 [TBL] [Abstract][Full Text] [Related]
4. Expression of aspartoacylase activity in cultured rat macroglial cells is limited to oligodendrocytes. Baslow MH; Suckow RF; Sapirstein V; Hungund BL J Mol Neurosci; 1999; 13(1-2):47-53. PubMed ID: 10691291 [TBL] [Abstract][Full Text] [Related]
5. The effects of lithium chloride and other substances on levels of brain N-acetyl-L-aspartic acid in Canavan disease-like rats. Baslow MH; Kitada K; Suckow RF; Hungund BL; Serikawa T Neurochem Res; 2002 May; 27(5):403-6. PubMed ID: 12064356 [TBL] [Abstract][Full Text] [Related]
6. Canavan's spongiform leukodystrophy: a clinical anatomy of a genetic metabolic CNS disease. Baslow MH J Mol Neurosci; 2000 Oct; 15(2):61-9. PubMed ID: 11220786 [TBL] [Abstract][Full Text] [Related]
7. Canavan disease and the role of N-acetylaspartate in myelin synthesis. Namboodiri AM; Peethambaran A; Mathew R; Sambhu PA; Hershfield J; Moffett JR; Madhavarao CN Mol Cell Endocrinol; 2006 Jun; 252(1-2):216-23. PubMed ID: 16647192 [TBL] [Abstract][Full Text] [Related]
8. Suppressing N-Acetyl-l-Aspartate Synthesis Prevents Loss of Neurons in a Murine Model of Canavan Leukodystrophy. Sohn J; Bannerman P; Guo F; Burns T; Miers L; Croteau C; Singhal NK; McDonough JA; Pleasure D J Neurosci; 2017 Jan; 37(2):413-421. PubMed ID: 28077719 [TBL] [Abstract][Full Text] [Related]
9. N-Acetylaspartate Synthase Deficiency Corrects the Myelin Phenotype in a Canavan Disease Mouse Model But Does Not Affect Survival Time. Maier H; Wang-Eckhardt L; Hartmann D; Gieselmann V; Eckhardt M J Neurosci; 2015 Oct; 35(43):14501-16. PubMed ID: 26511242 [TBL] [Abstract][Full Text] [Related]
10. Effects of ethanol and of alcohol dehydrogenase inhibitors on the reduction of N-acetylaspartate levels of brain in mice in vivo: a search for substances that may have therapeutic value in the treatment of Canavan disease. Baslow MH; Suckow RF; Hungund BL J Inherit Metab Dis; 2000 Nov; 23(7):684-92. PubMed ID: 11117430 [TBL] [Abstract][Full Text] [Related]
11. Brain N-acetylaspartate as a molecular water pump and its role in the etiology of Canavan disease: a mechanistic explanation. Baslow MH J Mol Neurosci; 2003; 21(3):185-90. PubMed ID: 14645985 [TBL] [Abstract][Full Text] [Related]
13. Nur7 is a nonsense mutation in the mouse aspartoacylase gene that causes spongy degeneration of the CNS. Traka M; Wollmann RL; Cerda SR; Dugas J; Barres BA; Popko B J Neurosci; 2008 Nov; 28(45):11537-49. PubMed ID: 18987190 [TBL] [Abstract][Full Text] [Related]
14. Evidence supporting a role for N-acetyl-L-aspartate as a molecular water pump in myelinated neurons in the central nervous system. An analytical review. Baslow MH Neurochem Int; 2002 Apr; 40(4):295-300. PubMed ID: 11792458 [TBL] [Abstract][Full Text] [Related]
15. Restoration of aspartoacylase activity in CNS neurons does not ameliorate motor deficits and demyelination in a model of Canavan disease. Klugmann M; Leichtlein CB; Symes CW; Serikawa T; Young D; During MJ Mol Ther; 2005 May; 11(5):745-53. PubMed ID: 15851013 [TBL] [Abstract][Full Text] [Related]
17. Ablating N-acetylaspartate prevents leukodystrophy in a Canavan disease model. Guo F; Bannerman P; Mills Ko E; Miers L; Xu J; Burns T; Li S; Freeman E; McDonough JA; Pleasure D Ann Neurol; 2015 May; 77(5):884-8. PubMed ID: 25712859 [TBL] [Abstract][Full Text] [Related]
18. N-Acetylaspartate in the CNS: from neurodiagnostics to neurobiology. Moffett JR; Ross B; Arun P; Madhavarao CN; Namboodiri AM Prog Neurobiol; 2007 Feb; 81(2):89-131. PubMed ID: 17275978 [TBL] [Abstract][Full Text] [Related]
19. NAAG synthetase deficiency has only low influence on pathogenesis in a Canavan disease mouse model. Becker I; Wang-Eckhardt L; Eckhardt M J Inherit Metab Dis; 2024 Mar; 47(2):230-243. PubMed ID: 38011891 [TBL] [Abstract][Full Text] [Related]
20. Are astrocytes the missing link between lack of brain aspartoacylase activity and the spongiform leukodystrophy in Canavan disease? Baslow MH; Guilfoyle DN Neurochem Res; 2009 Sep; 34(9):1523-34. PubMed ID: 19319678 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]